Rivastigmine in subcortical vascular dementia
The DOI matches its Crossref record; 40 of the 44 references it cites were found in a registry or an index.
Abstract
Further to recent data indicating that patients with vascular dementia (VaD) show a cholinergic deficit, we aimed to determine whether rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), has any effects on the symptoms of VaD. Patients aged 65-80, with a diagnosis of dementia and probable VaD, received rivastigmine 3-6 mg/day (n=8) or cardioaspirin (n=8) in an open study for 22 months. At 22 months, patients treated with rivastigmine showed significant improvements in executive function and behavioural symptoms (both p<0.05 vs. both baseline and control group), which were reflected in reduced caregiver stress (p<0.05 vs. baseline and controls). Baseline scores of global response, cognition, word fluency and activities of daily living were maintained in patients receiving rivastigmine, and there was no increase in benzodiazepine or neuroleptic intake. In contrast, the control group showed no improvements in any domain, and significant deterioration in global response and executive function (both p<0.05 vs. baseline and rivastigmine group). Side effects in both groups were tolerable and there were no study withdrawals. Long-term rivastigmine treatment appeared to be safe and effective in this patient population. In particular, improvements in domains particularly relevant to this condition were observed. These benefits may reflect the drug's dual inhibitory effects on the cholinergic system, and its particular activity in frontal areas of the brain. A large, double-blind study of rivastigmine in patients with VaD would be worthwhile.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One meta-analysis commented that the cognitive benefits of cholinergic agents and memantine were of uncertain clinical significance in VaD, and more data are required before widespread use of these agents is to be considered.411”
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · cited 1×
“Global cognitive function was assessed using the MMSE [30] at each visit.”
MethodAssessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living
Lawton, M. P., & Brody, E. M. (1969) · The Gerontologist · doi:10.1093/geront/9.3_part_1.179 · Cited by 18,540
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568 · cited 1×
“Behavioural symptoms were assessed using the NeuroPsychiatric Inventory (NPI) [37] at every visit.”
MethodA New Clinical Scale for the Staging of Dementia
Hughes, C. P., Berg, L., Danziger, W., Coben, L. A., & Martin, R. L. (1982) · British Journal of Psychiatry · doi:10.1192/bjp.140.6.566 · Cited by 7,056 · cited 1×
“In addition, global performance was assessed using the Clinical Dementia Rating [36] at every visit.”
MethodRomán, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
(1987) · PubMed · Cited by 2,657
Katz, S. (1963) · JAMA · doi:10.1001/jama.1963.03060120024016 · Cited by 2,421 · cited 1×
“At baseline, 12 months and 22 months, the index of Activity of Daily Living (ADL) [34] was used to test the performance of daily living activities, and the Instrumental Activity of Daily Living (IADL) [35] was used to assess in particular instrumental (as opposed to basic) activities.”
MethodFrontal-subcortical circuits and human behavior
Cummings, J. L. (1993) · Archives of Neurology · doi:10.1001/archneur.1993.00540080076020 · Cited by 2,262
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Erkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R., Lilienfeld, S., & Damaraju, C. V. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08267-3 · Cited by 752 · cited 1×
“Most previous clinical trials performed in patients with VaD have achieved unsatisfactory results [40], including a trial of the AChE-selective inhibitor galantamine, which showed efficacy in patients with AD with cerebrovascular disease, but not VaD [41], suggesting that the drug’s efficacy in the former subgroup may…”
Result
Research works printed but not linked: 1
- Wallin, 1989, Neurochemical abnormalities in vascular dementia, Dementia, 1, 120
Cited by
Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Pantoni, L. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70104-6 · Cited by 3,405
(2014) · International Journal of Stroke · doi:10.1111/ijs.12374_18 · Cited by 1,166
Post-stroke cognitive impairment: epidemiology, mechanisms and management.
(2014) · PubMed Central · doi:10.3978/j.issn.2305-5839.2014.08.05 · Cited by 680
“And the trials on rivastigmine suggested the effect on executive function in VCI (92,93).”
BackgroundTargeting acetylcholinesterase and butyrylcholinesterase in dementia
Lane, R. M., Potkin, S. G., & Enz, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005833 · Cited by 654
“Improvements in attention, executive dysfunction and behaviour have been demonstrated in patients with ischaemic subcortical vascular dementia treated with ChE-Is (Moretti et al., 2002, 2004).”
Background
Metadata
- Authors
- Moretti, R., Torre, P., Antonello, R. M., Cazzato, G., & Bava, A.
- Affiliations
- University of Trieste (IT)
- Venue
- Journal of the Neurological Sciences
- Publisher
- Elsevier BV
- Published
- 2002-11
- Volume
- 203-204
- Pages
- 141-146
- ISSN
- 0022-510X (ISSN-L)
- OpenAlex
- W2184923050
- Cited by
- 107
- References
- 44
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 1 · 2020: 7 · 2019: 2 · 2018: 1 · 2017: 4 · 2016: 1 · 2014: 3 · 2013: 3 · 2012: 3
- FWCI
- 8.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of the Neurological Sciences (publishedVersion)
- PubMed (publishedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- rivastigmine, vascular dementia, subcortical vascular dementia, acetylcholinesterase inhibitors, butyrylcholinesterase inhibition, cholinergic deficit, executive function, behavioural symptoms, caregiver stress, long-term drug safety
- MeSH terms
- Rivastigmine, Activities of Daily Living, Aged, Aged, 80 and over, Behavior, Carbamates, Cholinesterase Inhibitors, Female, Follow-Up Studies, Humans, Male, Neuropsychological Tests, Psychiatric Status Rating Scales, Stress, Psychological, Dementia, Vascular, Treatment Outcome, Caregivers, Neuroprotective Agents, Phenylcarbamates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rivastigmine in subcortical vascular dementia. https://app.cochat.ai/papers/10.1016/s0022-510x(02)00280-0
- The paper
- Moretti, R., Torre, P., Antonello, R. M., Cazzato, G., & Bava, A. (2002). Rivastigmine in subcortical vascular dementia. Journal of the Neurological Sciences. https://doi.org/10.1016/s0022-510x(02)00280-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.